December 07th, 17
Social Survey Research Information Co., Ltd.
Social Survey Research Information Co., Ltd.
NEWS
Launch of PatientsMap 2017 JP
2017 version includes pharmaceutical manufacturer's e-detailing data
Launch of PatientsMap 2017 JP
2017 version includes pharmaceutical manufacturer's e-detailing data
December 7th, 2017
Social Survey Research Information Co., Ltd.
On September 29th, 2017, SSRI and M3 launched the PatientsMap Japan 2017 version.PatientsMap is a database product which uncovers the types of diseases that various specialists see, and the monthly number of those patients. The data is collected from over 20,000 physicians covering approximately 400 diseases/conditions, and is utilized by over 50 companies in Japan.
In addition to the new PatientsMap Japan 2017 data, US data (2016 with n=5,000) and UK data (2015 with n=1,000) are also available.<< Characteristics of PatientsMap Japan 2017 version>>
- Able to understand the e-detailing (provision of information via internet) situation
Manufacturers' e-detailing data is a new item in the PatientsMap 2017 version. Since PatientsMap is a database with over 20,000 physicians, it allows you to understand which manufacturers have high e-detailing rates from various aspects, such as specialty and regions.
- Able to understand the physicians' level of trust (confidence) in various manufacturers
In the 2016 version, PatientsMap added a question (data) on the "level of trust (confidence) in pharmaceutical manufacturers". This question is also asked in the 2017 version.
- Uncovers the number of patients who were prescribed drugs
In addition to the "number of patients seen", from 2015 version, PatientsMap added a question (data) on the "number of patients who were prescribed drugs". This question is also asked in the 2017 version.
You can access the demo page here:
https://research.ssri.co.jp/pmap/?--lang=en
Outline of PatientsMap Japan 2017:
The study was conducted in collaboration M3 by using their portal site "m3.com" registered physicians of over 250,000. Respondents were sampled randomly per each specialty.| Targeted disease | 401 conditions/diseases |
| Study target | M3.com registered physicians |
| Inclusion criteria | Physicians working in hospitals and offices |
| Methodology | Online survey |
| Sample size | 20,135 |
| Fieldwork | April 19 ~ August 6th, 2017 |
| Study contents | - Diseases/conditions that they see - Number of patients that they see (per each disease) - Number of patients prescribed with drugs (per each disease) - Diseases in which they desire new drugs - Sales rep visitation - Level of trust/confidence in manufacturers - Received e-detailing |
■Contact Information (Social Survey Research Information Co., Ltd)
Chiharu Sakai (csakai@ssri.com)
Hitoshi Dennoh (hdennoh@ssri.com)
Tel: +81-3-3370-3474
■ Social Survey Research Information Co., Ltd
| Established | April 1982 |
| Capital | 27 million JPY |
| President & CEO | Takashi Makita |
| Number of staffs | 137 |
| Address | HQ (Tokyo) 5-1-14 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023 Osaka office 4-6-3 Hirano-Cho, Chuo-ku, Osaka 541-0046 |
| Affiliate companies | PD Research, SSRI CHINA |
| URL | http://www.ssri.com/ |
| Established | September 2000 |
| Capital | 15.3 billion JPY |
| Representative Director | Itaru Tanimura |
| Number of staffs | 4,370 |
| Address | 1-11-44 Akasaka, Minato-ku, Tokyo 107-0052 |
| URL | http://corporate.m3.com/ |